A Phase 1 Study of SGN-35T in People with Lymphoma

Full Title

Purpose

Researchers want to find the best dose of SGN-35T to use in people with lymphoma. The people in this study have Hodgkin or non-Hodgkin lymphoma that came back or keeps growing after treatment.

Many lymphoma cells have a protein called CD30 on their surfaces. This protein plays a role in cancer growth. SGN-35T attaches to CD30 and is designed to destroy cells containing this protein. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have lymphoma that came back or keeps growing after treatment and makes CD30.
• Have recovered from the serious side effects of prior anti-cancer therapies before getting SGN-35T.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Alison Moskowitz’s office at 646-608-3726.